SCHEMBL307903

SCHEMBL307903

C[n+]1cccc2ccccc21

nearest known ligand 0.57

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
ACHE P22303 11/20 0.53
BCHE P06276 8/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29752612 1.00 ACHE (0.53) ACHEBCHE
Iodide SCHEMBL29462677 0.97 ACHE (0.52) ACHEBCHE
Iodide SCHEMBL28357633 0.97 ACHE (0.52) ACHEBCHE
Hydrochloric Acid SCHEMBL27855884 0.97 ACHE (0.52) ACHEBCHE
Hydrochloric Acid SCHEMBL30383932 0.97 ACHE (0.52) ACHEBCHE
Bromide SCHEMBL5611688 0.97 ACHE (0.52) ACHEBCHE
Bromide SCHEMBL7776277 0.97 ACHE (0.52) ACHEBCHE
Hydrochloric Acid SCHEMBL2031419 0.97 ACHE (0.52) ACHEBCHE
Iodide SCHEMBL29462685 0.97 ACHE (0.55) ACHEBCHE
Iodide SCHEMBL336454 0.97 ACHE (0.55) ACHEBCHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 744 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118307524-A Endoplasmic reticulum targeting long-wavelength fluorescent probe for detecting hydroxyl radicals and preparation method and application thereof 遵义医科大学 2024-07-09 CN claimed
US-10752606-B2 Methods for treating protozoan infections NEOCULI PTY LTD. (AU) 2020-08-25 US claimed
US-20200102287-A1 METHODS FOR TREATING PROTOZOAN INFECTIONS NEOCULI PTY LTD (AU) 2020-04-02 US claimed
US-10562880-B2 Methods for treating protozoan infections NEOCULI PTY LTD. (AU) 2020-02-18 US claimed
US-20190330178-A1 METHODS FOR TREATING PROTOZOAN INFECTIONS NEOCULI PTY LTD (AU) 2019-10-31 US claimed
US-10392363-B2 Methods for treating protozoan infections NEOCULI PTY LTD. (AU) 2019-08-27 US claimed
US-20170291886-A1 METHODS FOR TREATING PROTOZOAN INFECTIONS NEOCULI PTY LTD (AU) 2017-10-12 US claimed
WO-2016076692-A2 SURFACTANT DERIVED FROM QUINOLINIUM FOR THE MODIFICATION OF CLAY MOROCCAN FOUNDATION FOR ADVANCED SCIENCE, INNOVATION & RESEARCH (MASCIR) (MA) 2016-05-19 WO claimed
US-8436055-B2 Modified acidic ion-exchange resin and method for preparing bisphenol MITSUI CHEMICALS, INC. (JP) 2013-05-07 US claimed
US-20100324341-A1 MODIFIED ACIDIC ION-EXCHANGE RESIN AND METHOD FOR PREPARING BISPHENOL TERAJIMA TAKASHI 2010-12-23 US claimed
WO-1996029312-A1 STILBAZOLIUM SALT, AND PREPARATION AND USE THEREOF ORION ELECTRIC CO., LTD. (KR) 1996-09-26 WO claimed
US-5393606-A Electroconductivity CIBA-GEIGY CORPORATION (US) 1995-02-28 US claimed
EP-0573387-A2 Charge-transfer complex with N-aromatic compounds, their preparation and their use CIBA-GEIGY AG (CH) 1993-12-08 EP claimed
EP-0249125-B1 PROCESS FOR THE PRODUCTION OF AN ELECTRICALLY CONDUCTIVE SURFACE LAYER ON MOULDED PLASTIC ARTICLES BASF Aktiengesellschaft (DE) 1991-10-16 EP claimed
US-4897289-A DISSOVING OR SWELLING THE SURFACE WITH A SOLVENT AND APPLYING AN ORGANIC ELECTRON ACCEPTOR, ORGANIC ELECTRON DONORS AND/OR IODIDES BASF AKTIENGESELLSCHAFT (DE) 1990-01-30 US claimed
US-4885368-A SEMICONDUCTORS, PHOTOCONDUCTORS, ELECTRODES, BATTERIES BASF AKTIENGESELLSCHAFT (DE) 1989-12-05 US claimed
EP-0206266-B1 RADICAL-ION SALTS BASF Aktiengesellschaft (DE) 1989-08-23 EP claimed
EP-0293749-A1 N,N'-Biscyano-p-benzoquinonebisimines, charge-transfer complexes containing them and radical-ion salts of the biscyano-benzoquinonebisimines BASF Aktiengesellschaft (DE) 1988-12-07 EP claimed
EP-0206266-A2 Radical-ion salts BASF Aktiengesellschaft (DE) 1986-12-30 EP claimed
US-4225497-A ACID CATALYSTS FOR IMIDATION RHONE-POULENC INDUSTRIES (FR) 1980-09-30 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100324341-A1 MODIFIED ACIDIC ION-EXCHANGE RESIN AND METHOD FOR PREPARING BISPHENOL PTMS, PHOSPHO1, ELL ACHE 4318/4885BCHE 2549/4885
US-20170291886-A1 METHODS FOR TREATING PROTOZOAN INFECTIONS DPM1, ABCB11, PIGS ACHE 280/4885BCHE 1135/4885
US-20200102287-A1 METHODS FOR TREATING PROTOZOAN INFECTIONS DPM1, ABCB11, PIGS ACHE 280/4885BCHE 1135/4885
US-20190330178-A1 METHODS FOR TREATING PROTOZOAN INFECTIONS DPM1, ABCB11, PIGS ACHE 280/4885BCHE 1135/4885
US-10562880-B2 Methods for treating protozoan infections DPM1, ABCB11, PIGS ACHE 280/4885BCHE 1135/4885
US-10752606-B2 Methods for treating protozoan infections DPM1, ABCB11, PIGS ACHE 280/4885BCHE 1135/4885
US-10392363-B2 Methods for treating protozoan infections DPM1, ABCB11, PIGS ACHE 280/4885BCHE 1135/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.